Evidence map›Paper›PMID 40707668›Full record

ArticleNPJ precision oncology2025

Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities.

Eunice S Li, Rebecca Ho, Ran Tao, Yannes Wai Yan Choi, Chae Young Shin, Shary Y Chen, Bengul Gokbayrak, Janine Senz, Betty Yao, Liam Johnston and 8 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Eunice S Li *Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Rebecca Ho *Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Ran TaoDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Yannes Wai Yan ChoiDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Chae Young ShinDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Shary Y ChenDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Bengul GokbayrakDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Janine SenzDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Betty YaoDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Liam JohnstonDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Spencer D MartinDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Eric YangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Mark S CareyDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
Bryan T HennessyRoyal College of Surgeons in Ireland, Dublin, Ireland.
David G HuntsmanDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Ramon I Klein GeltinkDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Lynn HoangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Yemin WangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. yemin.wang@ubc.ca.

Funding

Canadian Cancer Society Research Training AwardCanadian Graduate Scholarship Master's programCIHR PJT-178179Natural Sciences and Engineering Research Council of Canada RGPIN-2020-05390Terry Fox Research Institute PPG #1116VGH and UBC Hospital Foundation OVCARE
6 · The paper itself

Abstract

Endometrial carcinoma (EC), the most common gynecologic cancer type in developed countries, encompasses four molecular subtypes (POLEmut, MMRd, p53abn, and NSMP) that have prognostic values and guide treatment decisions. Additionally, dual loss of ARID1A and ARID1B (referred to as ARID1A/B) characterizes a significant portion of dedifferentiated/undifferentiated EC (DD/UDEC), a rare but highly aggressive subtype of EC. To advance the translational research for ECs, we analyzed the genomic features of a panel of 39 EC cell lines, leading to the identification of cell lines representing each of these EC molecular subtype. Histologic and immunohistochemical analyses of xenografted tumors from these cell lines confirmed their resemblance of cognate primary EC molecular subtypes. Further investigation of the publicly available genome-wide CRISPR screen data for EC cell lines identified multiple specific genetic dependencies in MMRd, p53abn, and ARID1A/B-dual deficient EC cell lines. Particularly, ARID1A/B-dual deficient DD/UDEC cells selectively rely on mitochondrial oxidative phosphorylation in vitro and in vivo. Therefore, through molecular subtyping of EC cell lines and subsequent characterization of molecular subtype-specific genetic dependencies, our study provides a framework that guides the utility of the EC cell line models for accelerating translational research in EC.

Identifiers

PMID40707668
PMCPMC12289969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.